title: Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapy.
abstract: Peptide receptor radionuclide therapy is routinely used for neuroendocrine tumors. To prevent radiopeptide retention at the proximal tubule of the kidney, positively charged amino are coinfused. However, hyperkalemia (>5.0 mmol/L) in more than three fourth of patients has been reported. In our case, the patient experienced acute hyperkalemia with blood values greater than 7.0 mmol/L with gastroparesis and subileus.
authors.affiliation: From the *Department of Nuclear Medicine, and †Institute of Radiology, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Rudolf A
authors.initials: RA
authors.lastname: Werner
authors.forename: Joachim
authors.initials: J
authors.lastname: Brumberg
authors.forename: Alexander
authors.initials: A
authors.lastname: Dierks
authors.forename: Ken
authors.initials: K
authors.lastname: Herrmann
authors.forename: Johannes
authors.initials: J
authors.lastname: Biko
authors.forename: Andreas K
authors.initials: AK
authors.lastname: Buck
authors.forename: Constantin
authors.initials: C
authors.lastname: Lapa
mesh_terms: D000596:Amino Acids / Q000009:adverse effects* / Q000627:therapeutic use; D018589:Gastroparesis / Q000209:etiology*; D006801:Humans; D006947:Hyperkalemia / Q000209:etiology*; D007668:Kidney / Q000187:drug effects*; D008297:Male; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods*; D018000:Receptors, Peptide / Q000378:metabolism
chemical_list: D000596:Amino Acids; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide